BerGenBio

Report Publication Announcement • Aug 13, 2024

BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast

BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast

Bergen, Norway, 13 August 2024- BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, will be announcing its results for the second quarter and

half year 2024 on Wednesday 21 August 2024. The briefing will take place at the

Conference "Vestland på Børs" at 09:45 am CEST where BerGenBio's senior

management team will provide a business update.

The presentation will webcast live, a link will be available at

www.bergenbio.com in the Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports) and a recording

will be available shortly after the webcast has finished. Direct link to the

webcast: BerGenBio Webcast Q2

2024 (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240821_12)

The second quarter and half year financial report and presentation will be made

available on the Company's website in the Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CEST

the same day.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to MAR

article 17 and section 5-12 of the Norwegian Securities Trading Act.